Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

291
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
291
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

3.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.2K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

257
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
257
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

48
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
48
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

38
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
38
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

362
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
362

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Development and validation of a multiancestry and multitrait polygenic risk score for lung cancer.

Nature communications·2026
Same author

Prediction Pipeline Selection for Incomplete Clinical Data via Missingness Fingerprints and Instance Augmentation.

Bioengineering (Basel, Switzerland)·2026
Same author

Infant-Type Bifidobacteria as Biocontrol Agents: Suppressing <i>Listeria monocytogenes</i> via Key Virulence Gene Alteration.

The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale·2025
Same author

Boosting the Power of Rare Variant Association Studies by Imputation Using Large-scale Sequencing Population.

Genomics, proteomics & bioinformatics·2025
Same author

Multi-Omics Analysis Revealed Characterization of Gastric Microbiome and Metabolome in Helicobacter pylori-Induced Progression of MASLD.

Helicobacter·2025
Same author

Evaluation of the risk of noise-induced hearing loss and the significance of occupational noise exposure limit among Chinese industrial workers.

The Journal of the Acoustical Society of America·2025

関連する実験動画

Updated: Sep 10, 2025

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.9K

2型糖尿病と高血圧の患者における心血管疾患の比較結果と低血糖薬の安全性:多センターコホート分析

Zhiyuan Wei1,2, Wanqian Xu3, Yu Wang4

  • 1Department of Medical Informatics, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, 211166, Jiangsu, China.

Cardiovascular diabetology
|August 21, 2025
PubMed
まとめ

2型糖尿病および高血圧の患者では,グルカゴン類ペプチド1受容体アゴニストおよびディペプチドルペプチダース4阻害剤は,インスリンと比較して,心臓血管に関するより良い結果を示しています. これらの発見は 糖尿病と高血圧を効果的に管理するための 重要な洞察を与えてくれます

キーワード:
心血管の安全性高血圧重大心血管疾患 (MACE)現実世界の証拠遡及的研究2 型糖尿病

さらに関連する動画

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.0K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

371

関連する実験動画

Last Updated: Sep 10, 2025

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.9K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.0K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

371

科学分野:

  • 心臓病科
  • 内分泌学
  • 薬理学について

背景:

  • 2型糖尿病 (T2D) と高血圧の患者は,心血管疾患 (CV) のリスクが高まります.
  • この集団における主要な低血糖薬のCV有効性と安全性を比較する実際のデータは限られている.

研究 の 目的:

  • 高血圧のT2D患者における主要な低血糖剤のCVアウトカムと安全性プロファイルを直接比較する.
  • この高リスクグループにおけるT2D管理の最適化のための実用的な証拠を提供するためです.

主な方法:

  • メトホルミンを服用した高血圧のT2D患者の電子医療記録の多中心集積分析.
  • 添加された薬物クラス (インスリン,SU,GLP-1RA,DPP4is,グリニド,アカルボス,SGLT2is) の3/4ポイントのMACEと安全性結果を比較するための傾向スコアマッチングとコックス比例リスクモデル.

主要な成果:

  • GLP- 1 RAs,DPP4is,およびglinidesは,インスリンと比較して3ポイントMACEのリスクが低いことを示した.
  • DPP4is,GLP- 1RA,およびグリニドは,アカルボースと比較して3点MACEのリスクが低かった.
  • DPP4は慢性腎疾患のリスクの低下と関連しているが,冠動脈硬化症や高血圧性心疾患のリスクは増加している.

結論:

  • 低血糖治療は,高血圧のT2D患者に対して,現実の環境で異なるCV有効性と安全性を示しています.
  • この発見は,心血管疾患の改善と安全性に関する懸念に対処するために,低血糖剤の適正な選択を支持する.